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Antidepressant therapy in primary care: Does patient preference affect response? 
Context Current research and practice guidelines support the use of both 
psychotherapy and pharmacotherapy for the treatment of depression in primary care. 
Identifying predictors of response to therapy can assist patients and providers in 
choosing the most effective treatment for individual patients. 
Objective To assess the effect of patient treatment preference on therapeutic outcome 
in a trial of antidepressant therapy for patients with depressive symptoms. 
Design Secondary analysis of a randomized, controlled trial of 3 selective serotonin 
reputake inhibitors (SSRis) in primary care. 
Setting & Participants A total of 573 patients with symptoms warranting antidepressant 
therapy in 37 primary care practices organized in 2 U.S. primary care research 
networks. 
Intervention Participants were queried at baseline about the acceptability of 
antidepressants, counseling, and waiting as treatments for depression before being 
randomized to one of three SSRis. 
Outcome Measures The two primary outcomes were 1) depressive symptoms, 
measured by the Symptoms Checklist (SCL-20), and 2) functional status, measured by 
the Medical Outcomes Study 12-ltem Short Form Health Survey Mental Component 
Summary Score (MCS-12). Outcomes were assessed by telephone interview at 1, 3, 6, 
and 9 months after initiation of antidepressant therapy. 
Results Patients were categorized as having a strong antidepressant preference (23%), 
mild antidepressant preference (48%), counseling preference (12%), or a preference for 
waiting (17%). Logistic regression revealed that white race, longer chronicity of 
symptoms, and a past history of depression treatment were significantly associated with 
a strong antidepressant preference versus other groups. Longitudinal models 
demonstrated significant time by preference group interactions for both SCL-20 (p < 
0.001) and MCS-12 (p < 0.001) scores, adjusting for baseline covariates of age, gender, 
race/ethnicity, anxiety, chronicity of symptoms, past history of depression treatment, and 
medical comorbidity. 
Conclusions Patients who believe antidepressants are a definitely acceptable 
treatment for depression respond more rapidly to SSRI therapy than other patients. 
Patient treatment preference is a significant predictor of the rate of response to 
pharmacotherapy for depression. 
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Introduction 
Patient-centered care is a clinical approach characterized by medical decision-
making that is responsive to the knowledge, attitudes, and beliefs of individual patients. 1 
In this sense, patient-centered care reflects a professional evolution away from traditional 
approaches that focus on disease specifics and physician authority. The value of the 
patient -centered approach has been validated both by surveys that indicate that patients 
want such a focus in primary care appointments2 and by research in multiple medical 
~-
specialities demonstrating that this approach to improving communication produces L 
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better health outcomes. 3 Addressing patient preferences for treatment is an important 
T--
component of the patient -centered approach. 
Both depression-specific psychotherapy and antidepressants produce similar 
clinical benefit in patients treated for depressive disorders.4•5•6 Because of their equal 
efficacy, the 1998 Agency for Health Care Policy and Research (AHCPR) practice 
guidelines for the treatment of major depression in primary care conclude that either 
treatment is acceptable and that, because predictors of response to either therapy are not 
well understood, patients' preferences should be taken into account in making decisions 
regarding therapy.7 Despite these specific guidelines many primary care patients do not 
receive adequate therapy for depression, 8 and it is unclear to what extent patient 
preferences are elicited and incorporated into treatment plans. 
Surveys of both depressed and general primary care patients indicate that a 
majority of patients want active treatment for depression, and that a majority of those 
" . . f I' 'd 9 Io u C . I pre,ernng active treatment pre er counse mg to anti epressants. · · ross-sectwna 
studies have correlated patient treatment preferences with a host of medical and 
2 
demographic variables, including gender, race/ethnicity, knowledge about treatment, past 
history of treatment, and income. 10 Despite the clear evidence that patients prefer 
counseling for the treatment of depression, few patients in primary care receive 
psychotherapy and little research has investigated the effect that preferences have on 
treatment outcomes. Two partially randomized patient preference trials conducted in the 
United Kingdom have assessed the effect of preferences on outcome for both 
antidepressants and counseling.12•13 The studies employed a design in which patients 
were recruited and randomized to alternative treatments; those who refused 
randomization but agreed to participate were allowed to choose between alternative 
treatments, producing four arms: two randomized treatment arms and two preference 
arms. Comparing those who chose antidepressants to those randomized to I 
antidepressants, no effect on outcome was documented for preference, but one study did 
find improved outcomes for those preferring counseling compared to those randomized to 
counseling. 
The equivalence of antidepressants and psychotherapy in the treatment of 
depression underscores the importance of defining predictors of therapeutic response in 
order to realize safe, effective, and cost-effective care. Among the confirmed predictors 
for persistence of symptoms and unresponsiveness to therapy are initial severity of 
d . 14 . . 14 h . . f 15 d b'd . d' d 16 epress10n, neurotJcrsm, c romcrty o symptoms, an comor 1 pamc rsor er. 
Providing patients with treatments that are consonant with their individual values may 
offer an opportunity to improve outcomes. To further assess the relationship between 
treatment preference and therapeutic outcomes, we investigated whether patient 
preferences for treatment affected response to antidepressant therapy in a randomized trial 
3 
of selective-serotonin reuptake inhibitors (SSRls) in primary care. We hypothesized that 
patients who preferred antidepressant therapy would have a greater response to medical 
therapy than other patients. 
l 
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METHODS 
Enrollment & Design 
A Randomized Trial Investigating SSRI Treatment (ARTIST) was designed to 
compare the effectiveness of 3 SSRis in a primary care setting; full details of its 
methodology have been published elsewhere. 17 Briefly, patients were enrolled over an 
eight-month period in 1999 in 2 primary care research networks. Eligible patients were 
aged at least 18 years, received their primary care from a participating provider, and were 
judged by their provider to have a depressive disorder that merited antidepressant therapy. 
Exclusion criteria included severe cognitive impairment, terminal illness, actively 
suicidal, recent or current SSRI use, current non-S SRI antidepressant use, and pregnancy, 
breastfeeding, or planning pregnancy. The ARTIST study was approved by the relevant 
institutional review boards; our substudy was approved by the institutional review boards 
of Duke University and the University of North Carolina School of Public Health. 
Clinic personnel obtained informed consent after the primary-care physician 
(PCP) deemed antidepressant therapy warranted due to clinical suspicion of a depressive 
disorder. Using a telephone procedure, patients were randomized by balanced blocks to 
one of three treatment regimens: 20 mg of paroxetine, 20 mg of fluoxetine hydrochloride, 
or 50 mg of sertraline. Neither patients nor PCPs were blinded to treatment, and the PCP 
could adjust the dose or change antidepressant based on clinical response. To defray the 
costs of therapy, enrolled patients were provided with a pharmacy benefits card that 
covered the cost of SSRI and non-SSRI antidepressants that the PCP prescribed during 
the 9 month trial. Outcomes were assessed with telephone interviews, with all 
information, save for suicidal ideation, concealed from PCPs. Study participants were 
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financially compensated on a per-interview basis, with a maximum total reimbursement 
of $150. 
Baseline Assessment 
Patient preferences were assessed with the three questions: "When you feel sad, 
how acceptable is it for you to ... 1) wait and get over it naturally, 2) use anti-depressant 
drugs, and 3) seek one-on-one counseling from a mental health professional?" Possible 
patient responses were "Definitely acceptable," "Probably acceptable," "Probably not 
acceptable," "Definitely not acceptable," or "Don't know." Using responses to the 
baseline treatment preference questions, patients were assigned to one of four mutually 
exclusive preference groups: 1) those responding that antidepressants were definitely 
acceptable (strong antidepressant preference), 2) those responding that antidepressants 
were probably acceptable (mild antidepressant preference), 3) those who felt that 
antidepressants were either probably not or definitely not acceptable but responded that 
counseling was definitely or probably acceptable (counseling preference), or 4) those who 
felt that neither antidepressants nor counseling was definitely or probably acceptable 
(waiting preference). For group assignment, "Don't know" was treated as a response of 
unacceptable. 
We measured patient characteristics that affect response to antidepressant therapy, 
including severity and chronicity of depression, prior history of depression treatment, 
coexisting anxiety disorder, and comorbid medical conditions. 14-16 Chronicity of 
symptoms was approximated by grouping diagnoses as determined by patient responses 
to questions assessing the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) depressive disorder diagnostic criteria. Patients were grouped into 
6 
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either 1) double depression or dysthymia, 2) major depression or bipolar disorder, 3) 
minor depression, or 4) no depressive diagnosis. Because some patients had multiple 
diagnoses, the diagnosis of double depression or dysthymia took prominence. Patients 
were queried for any past treatment for depression, and anxiety was assessed with a three-
question anxiety disorder screen adapted from the Primary Care Evaluation of Mental 
Disorders (PRIME-MD), with questions assessing generalized anxiety and panic 
attacks. 18 Although specific report of medical comorbidities was unavailable, self-report 
of baseline medication use was used to calculate each patient's Chronic Disease Score 
(CDS), a validated proxy for comorbid conditions that is highly correlated with individual 
' 
health care costs and mortality.19 I Outcome Measures 
r 
There were two outcomes for assessing response to therapy. Depressive 
symptoms were assessed with the Symptoms Checklist 20 (SCL-20), a subset of the 
Hopkins Symptom Checklist and Brief Symptom Inventory that has been validated as a 
f d . . . al d . d 'al f d . h 20 21 22 measure o epresston seventy m sever ran om1ze tn s o epresston t erapy. ' ' 
Lower scores on the SCL-20 indicate fewer depressive symptoms, and a mean (SD) 
depressive symptom score of '1.11!1 1:l'J:Til) for the U.S. population has been reported.Z3 
Functional status was measured by the Medical Outcomes Survey 12-Item Short-Form 
Health Survey Mental Component Summary (MCS-12), which incorporates four of the 
SF-12 subscales into a composite measure of mental health and is highly correlated with 
the more extensive SF-36 MCS.24 Higher MCS-12 scores indicate better functional 
status, and normative testing has established the mean (SD) MCS-12 score for the U.S. 
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population as 50.04 (9.6), with a range of 10-70.24 All outcomes were assessed at 1, 3, 6, 
and 9 months after beginning antidepressant therapy. 
Statistical Analysis 
Descriptive statistics, including means, standard deviations, medians and ranges, 
were calculated for all baseline variables. To examine baseline differences between 
groups, means of continuous variables and percentages of categorical variables were 
compared with one-way analysis of variance (ANOVA) (or Kruskal-Wallis analysis of 
variance where appropriate) and Pearson's chi-square test, respectively.25 
Using the baseline data, a multinomial logistic regression model was used to 
determine independent predictors of preference group, in order to identify potential 
co variates for the main statistical model. 25 Categorical variables for chronicity and race 
were entered into the model as indicator variables. The model was refined with reverse 
stepwise elimination of variables, with each successive model compared to the saturated 
model with the likelihood ratio test.25 A P-value < 0.05 was considered to be significant 
for all analyses. 
To describe the longitudinal outcome variables, mean changes in scores both from 
baseline and from previous timepoint were calculated for each preference group. Mean 
scores of both outcomes- SCL-20 and MCS-12- were compared between preference 
groups at each timepoint using oneway ANOVA.25 In order to utilize the advantage of 
multiple observations on single individuals, repeated-measures analysis of covariance 
(ANCOV A) models for both outcomes were used to better analyze the data 
longitudinally.25 The models incorporated both the main effects of interest- preference 
group and preference group by month- but also the baseline co variates for age, gender, 
8 
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race/ethnicity, baseline anxiety score, baseline SCL-20 or MCS-12 score, chronicity of 
symptoms by depressive diagnosis, past history of depression treatment, and the Chronic 
Disease Score. 
To better incorporate both fixed and random effects, the data were reanalyzed in 
collaboration with statisticians at the Durham, NC VA Medical Center using linear 
mixed-effects models to compare the changes in the main outcomes over time between 
preference groups.; The mixed effects model incorporates both the fixed effects of 
treatment and covariates and the random effects of individual variability in outcome .26 
Main fixed effects were preference group and both linear and quadratic month by group 
interactions. Random effects were included for patient and physician. Initial models for 
both outcomes incorporated only the preference groups and their interaction with both 
linear and quadratic time variables. Secondary models for both outcomes included not 
only the main exposure-outcome axis, but also the covariates representing age, gender, 
race/ethnicity, baseline anxiety score, chronicity of symptoms by depressive diagnosis, 
past history of depression treatment, randomized SSRI, and the Chronic Disease Score. 
Using these models, predicted values of the outcome scores over time were calculated. 
All analyses were performed using STAT A v7.0 (STAT A Corp., College Station, TX), 
except the mixed-effects model, which was fit using PROC MIXED in SAS v8.0 (SAS 
Institute, Cary, NC). 
'Thanks to Maren Olsen, Ph.D. and Di Liu of the Biostatistics unit of the Institute for Clinical and 
Epidemiologic Research at the VA Medical Center in Durham, NC, for developing the mixed-effects 
models. 
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RESULTS 
Baseline Characteristics 
Participant flow through ARTIST is shown in Figure 1. Of the 688 patients 
invited to participate, 601 were randomized to one of three SSRI treatments and 573 
completed the baseline telephone assessment. Follow-up interviews were successfully 
completed in 94% of patients at 1 month, 87% at 3 months, 84% at 6 months, and 79% at 
9 months. 
Waiting as a treatment for depression was definitely or probably acceptable to j b 
83% of participants, while antidepressants were acceptable to 71% and counseling to 66% 
(Table 1). The strong antidepressant preference group comprised the 131 patients who I responded that antidepressants were definitely acceptable, and the 276 patients who 
r 
responded that antidepressants were probably acceptable composed the mild 
antidepressant preference group. Of the remaining patients, 68 found counseling to be 
definitely or probably acceptable and constitute the counseling preference group, and the 
remaining 98 patients found neither antidepressants nor counseling acceptable and were 
assigned to the waiting preference group. 
Characteristics of the 573 patients completing the baseline interview are shown in 
Table 2 by assigned preference group. Overall, the mean age of study participants was 
46, and 79% were women; the study population was 84% white and 13% black. As 
assessed by the PRIME-MD, 73% of participants had major depression, 48% had 
dysthymia, 42% had double depression, and 8% had minor depression. Baseline scores 
on the main depression outcome scales described a study population with moderately 
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severe depression with mean (SD) scores of 1.66 (0.7) on the SCL-20 and 32.6 (11.5) on 
the MCS-12. 
Significant differences between preference groups were observed for age, race, 
depressive disorder diagnosis, and past history of depression treatment. While 9.9% of 
the strong antidepressant preference group had no depressive diagnosis by the PRIME-
+-
MD, 25.5% of the waiting preference group had no diagnosis. By preference group, mean 
(SD) baseline SCL-20 scores ranged from 1.43 (0.82) for the waiting preference group to 
t--
1.86 (0.76) for the strong antidepressant preference group, with the baseline differences in 
SCL-20 scores by exposure group significant (P = 0.0001) (Table 3). Post-hoc pairwise 
: 
comparisons between preference groups using the student's t -test revealed that the group I with a strong antidepressant preference was significantly different from all other groups. 
,-
Mean (SD) baseline MCS-12 scores ranged from 36.7 (13.0) for the waiting preference 
group to 28.3 (10.6) for the strong antidepressant preference group, with baseline scores 
again significantly different between exposure groups (P < 0.0001) (Table 4). The mean 
MCS-12 score for the group with a strong antidepressant preference was significantly 
different from all three other groups. 
Of demographic variables and potential covariates, race (P = 0.032), chronicity of 
symptoms (P = 0.044), and past history of depression treatment (P < 0.001) were 
independently associated with preference group. Patients who were white, had more 
severe or chronic depressive symptoms, or had been treated for depression previously 
were more likely to have a strong antidepressant preference than to prefer counseling or 
waiting. Age, gender, experiencing recent panic attacks, and the Chronic Disease Score 
were not significant! y associated with preference group. 
11 
Response to Therapy 
Patients in all preference groups demonstrated substantial improvement as 
measured by SCL-20 and MCS-12 scores during the study. The overall mean SCL-20 
score improved from 1.66 to 0.78; the overall mean MCS-12 score increased from 32.59 
to 48.75. Change in both scores was greatest in the first month after treatment initiation, 
and the rate of improvement in scores decreased during subsequent intervals. The 
original ARTIST results demonstrated that all three SSRis produced equivalent outcomes 
t--
in this group of patients. 17 
Tables 3 and 4 summarize the change over time in SCL-20 and MCS-12 scores, 
respectively, by treatment preference group. Figures 2 and 3 illustrate these score 
changes graphically. Although scores on both outcomes are significantly different at 
baseline between preference groups for both SCL-20 (P = 0.0001) and MCS-12 (P < 
0.0001), this difference was insignificant in subsequent measures. 
Patients with a strong antidepressant preference demonstrated greater 
improvement in scores than other groups (Figures 4 and 5). While SCL-20 scores 
decreased by a mean of 1.10 by 9 months in the strong antidepressant preference group, 
mean decreases in the other three groups ranged from 0.75 to 0.87 (Table 5). Similarly, 
mean MCS-12 scores improved by 21.1 at 9 months among those with a strong 
antidepressant preference, while mean improvements in other groups ranged from 11.9 to 
15.3 (Table 6). 
Longitudinal analyses revealed that mean SCL-20 and MCS-12 scores for the 
strong antidepressant preference group improved faster than scores for the other groups. 
The ANCOV A models documented significant group by time interactions for both SCL-
12 
20 (P = 0.0001) and MCS-12 (P < 0.0001) models. The mixed-effects model for the 
SCL-20 indicated significant interactions for both group by time (P = 0.0005) and group 
by time2 (P = 0.0368). The mixed-effects model for the MCS-12 supported a significant 
interaction only for group by time (P = 0.0002), with a nonsignificant interaction for 
group by time2 (P = 0.0660). For tbe mixed-effects models, the strong antidepressant 
preference group was the referent category for all tests. Predicted scores for both SCL-20 
and MCS-12 over time for the preference groups based on the mixed-effects models are 
presented in Figures 6 & 7. 
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DISCUSSION 
In this study we demonstrate that primary care patients with clinical depression 
meriting antidepressant therapy who report that antidepressants are definitely acceptable 
respond more quickly to antidepressant therapy than do those who prefer counseling or no 
treatment at all. Response to therapy was assessed with instruments measuring both 
depressive symptom severity and functional status. Although patients in all preference 
groups experienced substantial improvements on these measures during the study, 
baseline patient preferences significantly affected the rate of response. This effect was 
adjusted for the confounding influences of patient demographics and medical histories, 
and was detected with sound longitudinal statistical analyses. 
The ARTIST study was designed to simulate typical primary care treatment, 
allowing a great deal of latitude in treatment options and disease management. Because 
of the absence of artificial study requirements other than randomization to an SSRI, we 
believe that the study accurately reflects therapeutic conditions and patient response in 
primary care settings. We investigated patient preferences and treatment outcome in a 
study in which all patients were recruited with the knowledge that they would receive 
antidepressant therapy. This selection method had the potential to minimize differences 
in outcomes between preference groups by eliminating those patients who were more 
opposed to pharmacotherapy. Because of this, it is possible that the effect of preference 
on treatment outcome is larger than we report. 
Patient Preferences 
The patient preferences elicited with our assessment are similar to those of other 
studies. Interviewing 368 primary care patients who met the Composite International 
14 
L 
l 
f 
r 
! 
I 
Diagnostic Interview criteria for a major depressive episode, Cooper-Patrick et al. found 
that while 86% of patients considered individual counseling to be an acceptable 
treatment, only 70% considered antidepressants acceptable and 69% responded that 
waiting and getting over it naturally was acceptable.27 Dwight-Johnson et al. surveyed 
depressed primary care patients about treatment preferences; over 80% preferred active 
treatment to no treatment, and a majority of those preferring active treatment would 
choose counseling over antidepressants.10 Churchill et al. found that 51% of consecutive 
primary care patients preferred counseling and 15% favored pharmacotherapy.9 Our 
findings were notable for a greater acceptability of waiting than either active treatment, 
I 
I and a greater acceptability of antidepressants than counseling. We selected for patients who were amenable to antidepressant therapy and we included patients with no 
depressive diagnosis (approximately 12% of patients), resulting in a different patient 
population with slightly different preferences. 
The difference in preferences between studies highlights the variability in methods 
used to elicit treatment preferences. Cooper-Patrick et al. used an instrument similar to 
ours, which relied on basic questions about single treatments with a range of answers 
regarding acceptability. In contrast, Churchill et al. presented patients with four 
treatment options which they were instructed to rank in order of preference; Dwight-
Johnson et al. employed a single question about five treatments which described the cost, 
duration, and probability of success of each treatment, and which required patients to 
choose the one treatment they preferred. Forcing patients to choose the most preferred 
method prevents overlap of acceptable treatments, and incorporating specific treatment 
information reduces potential knowledge deficits. However, without a validated and 
15 
consistent instrument for eliciting patient preferences, drawing general conclusions from 
research in this field will be difficult. 
Despite the heterogeneity of preference assessment instruments, our preference 
groups reflect previous patient profiles. We found that white patients, more severely and 
chronically depressed patients, and those with a history of depression treatment were 
more likely to have a strong preference for antidepressants. Dwight-Johnson et al. found 
that antidepressant preference was more likely among patient who were white, female, 
had more knowledge of treatments, had a history of treatment, and had higher incomes. 
Similarly, a more limited assessment by Cooper-Patrick et al. found that African 
Americans were more likely to find medications unacceptable than white patients.27 Our 
study rested heavily on extracting a convincing measure of preference as our main 
exposure variable, and the fact that our categorization scheme agrees with previous 
research validates its application. 
Treatment Outcomes 
We document an association between patient preference and response to 
antidepressant therapy. Previous studies of patient preference and treatment outcome in 
depression have produced mixed results. The United Kingdom Counseling versus 
Antidepressants in Primary Care Study Group conducted a partially randomized 
preference trial that allowed patients to refuse randomization to either counseling or 
antidepressants and choose between the treatments. Although patient preference for 
either antidepressants or counseling conferred no improved outcome at 8 weeks28, at 12 
months the patients choosing counseling had slightly better outcomes than those 
randomized to counseling. 12 A second trial from the UK with randomized and patient 
16 
preference arms that evaluated the effectiveness of counseling, cognitive-behavior 
therapy, and usual care in depressed primary care patients found no significant differences 
in depression outcome measures between patients who chose psychological treatments 
and those who were randomized to them. 13 Rost et al. found that the improvement in 
depression severity attributable to a quality of care enhancement program was potentiated 
in patients who found antidepressants to be acceptable.29 Although this suggests that 
preference plays some role in treatment response, our study is the first that we know of to 
directly demonstrate improved outcomes with antidepressant therapy for patients who 
prefer antidepressants. L 
Our study differs from the preference trials in that all patients were recruited for 
and assigned to antidepressant therapy regardless of preference, patient preferences were 
elicited with a more indirect method of assessment, and our study was conducted in the 
United States, where attitudes towards and knowledge of depression treatment may vary 
from those in the U.K. Our results suggest the need for more research in the United 
States exploring depression treatment preferences and their effect on therapeutic 
outcomes. 
A more immediate concern is the clinical significance of the differential response 
we document. The overall changes in scores from baseline represent clinically important 
improvements, as this patient population achieved scores after 9 months of therapy that 
are consistent with population norms. The clinical importance of the differential 
improvement between preference groups is more difficult to judge. Although patients 
with a strong preference for antidepressants have greater improvement in scores and 
respond more rapidly to antidepressants, mean scores for all four preference groups were 
17 
similar at 9 months, indicating that a comparable level of depressive symptom severity 
and functional status was achieved with pharmacotherapy. This suggests that prescribing 
antidepressants- regardless of patient treatment preference- produces depressive 
symptom severity and functional status after 9 months of therapy comparable to 
population norms. Because we document increased rates of improvement with strong 
preference for antidepressants, however, our study implies that preference affects the 
amount of time needed to improve clinically significant improvements in symptoms and 
functional status. 
Limitations 
Our study has several limitations. First, by assigning all patients to antidepressant L 
therapy regardless of patient preference, our study differs from existing research on the 
effect of treatment preference on treatment outcome in that patients were not necessarily 
treated with their preferred therapy; regardless of preference, all patients received 
antidepressant therapy. Although this is less ideal than other study designs, it may more 
accurately reflect the reality of depression treatment in the United States, where 
preferences are often unaddressed and physicians are increasingly utilizing 
pharmacotherapy at the expense of psychological treatment.30 
Second, our treatment preference groups were defined indirectly, by abstracting 
f--
them from responses to questions regarding the acceptability of treatment rather than 
treatment preference. However, the preference groups we developed reflect previous 
research that has demonstrated differences in preferences associated with race/ethnicity, 
chronicity of symptoms, severity of symptoms, and past history of treatment.10 
18 
Third, because of the nature of our study, baseline characteristics between patients 
in the four preference groups were different, notably with respect to chronicity of 
symptoms (as approximated by the depressive disorder diagnosis) and severity of 
symptoms (as measured by both the SCL-20 and the MCS-12). Because of the confirmed 
impact of chronicity and severity of depression on treatment outcome, 14•15 these 
differences had the potential to confound the relationship under investigation between 
preference and outcome. Because of this, our longitudinal models incorporated the 
chronicity of symptoms as a covariate and accounted for the severity of symptoms at 
baseline. The possibility still exists, however, that an unmeasured and maldistributed L 
I factor produced the differences between preference groups that we document. Implications 
Our patient preference groups were designed with an eye towards clinical 
r 
relevance. While more narrowly-defined groups may have provided sharper contrasts 
between groups and more distinct patient profiles, we chose a simplified categorization 
scheme which is more amenable to rapid clinical assessment. Our preference groups can 
be reproduced with a two-step clinical evaluation: 1) assessing the degree of 
antidepressant acceptability, and 2) assessing the degree of counseling acceptability 
among those who find antidepressants unacceptable. Although this may not produce the 
L 
most precise representation of treatment preferences, its association with treatment 
response validates its utility as a clinical tool. 
While assessing preferences in clinical settings may be easy, effectively treating 
patients who are less like! y to respond to antidepressants is more difficult. Although the 
AHCPR guidelines recommend both antidepressants and counseling with equal vigor, 
19 
this recommendation is relevant only when a proven counseling program is accessible. 
While primary care physicians have relatively uniform access to antidepressant 
medication, access to effective counseling programs in the United States is more 
restricted. With a finite number of counselors, few counseling programs proven to be 
effective, and differential insurance coverage for psychotherapy compared to medical 
therapy, barriers to receiving counseling for depression are numerous. We investigated 
only the effect of preference on antidepressant therapy response, but we may presume that 
patients who prefer counseling respond more quickly to counseling than other patients. 
Accommodating those patients and providing the most effective and efficient treatment 
will be difficult without changes in the current mental health system to make effective L 
counseling programs more accessible. 
Our study documents an association between a strong preference for 
antidepressants and improved treatment outcome; we are unable to confirm a causal 
relationship between this preference and improved outcome. If we infer a causal link 
between the two, we may surmise that improving patient perceptions of antidepressants 
and thus making them more preferable is a potential means to improve treatment 
outcomes. Patients voice a variety of concerns about antidepressants, mainly regarding 
their side effects, addiction potential, and the necessary length of treatment.31 Addressing 
these concerns about pharmacotherapy may make them more acceptable to patients and 
cause them to respond more quickly than if they were less accepting of antidepressants. 
Such patient education could be done on an individual level at the outset of therapy or 
through wider, population-level information campaigns. 
20 
Do these results advocate allowing patient preferences to guide depression 
treatment? The difficulty in designing treatment plans for patients with depressive 
disorders lies in predicting which treatment will be effective for an individual patient. 
Our results confirm that a strong preference for antidepressants is a significant predictor 
of improved response to antidepressant therapy, suggesting it is best to accommodate 
these patients with pharmacotherapy. How best to accommodate patients with other 
preferences and ensure the provision of the most effective and efficient care should be the 
focus of further efforts to apply the principles of patient -centered care to improve 
depression outcomes in primary care. 
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Figure 1. Study Enrollment and Follow-up by Preference Group 
688 Patients Invited to Participate 
87 Refused Participation r-
601 Randomized 
573 Completed Baseline Assessment 
I 
I I I I 
131 Assigned to Strong 276 Assigned to Mild 68 Assigned to Counseling 98 Assigned to Waiting 
Antidepressant Preference Antidepressant Preference Preference Preference 
I I 
Outcome Assessment Outcome Assessment Outcome Assessment Outcome Assessment 
! 
L 
124at1mo 261 at 1 mo 62at1 mo 91at1mo 
115at3mo 245at3 mo 60at3mo 84at3mo 
114at6mo 231 at6mo 56at6mo 82at6mo 
107at9mo 222 at 9 mo 55at9mo 70at9mo L 
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Table 1. Baseline Responses to Patient Treatment Preference Questions 
Response,% 
Definitely acceptable 
Probably acceptable 
Probably not acceptable 
Definitely not acceptable 
Don't know 
Antidepressants 
22.9 
48.2 
16.1 
10.0 
3.0 
Mental Health 
Counseling 
25.3 
40.7 
20.1 
12.7 
1.2 
Table 2. Baseline Characteristics of Patients by Preference Group 
Variable Strong Mild Counseling 
antidepressant antidepressant preference 
preference preference (n=68) 
n-131) (n-276) 
Age, mean (SD), y • 45.0 (15.3) 44.8 (16.4) 47.2 (12.2) 
Women,% 82.4 79.7 82.4 
Race, o/o ** 
White 90.1 87.7 70.6 
Black 9.2 9.4 22.1 
Other 0.8 2.9 7.3 
Depressive d/o diagnosis, % ** 
Major depression/bipolar d/o 34.4 30.1 36.8 
Minor depression 4.6 8.3 8.8 
Double depression/dysthymia 51.2 54.4 36.8 
None 9.9 7.3 17.7 
Past history of depression 44.3 35.9 25.0 
treatment, % ** 
Anxiety score, mean (SD) 2.18 (0.7) 2.11 (0.8) 1.98 (0.8) 
Chronic Disease Score, median 1 (0-9) 1 (0-9) 1 (0-9) 
ran e 
No alcohol last mo., % 54.2 51.5 55.9 
SSRI randomized, % 
Fluoxetine 31.3 33.5 45.0 
Paroxetine 31.3 31.0 31.7 
Sertraline 37.4 35.5 23.3 
Health care resource utilization, 
median (range) 
Primary care visits, last 3 mo 1 (0-30) 1 (0-10) 1 (0-11) 
Psychiatrist visits, last 3 mo 0 (0-5) 0(0-12) 0 (0) 
Mental health visits, last 3 mo 0 (0-15) 0 (0-13) 0 (0-3) 
ER visits for mental health, 
last 3 mo 0 (0-20) 0 (0-2) 0 (0-2) 
Hospital days for mental 
health, last 12 mo 0 (0-6) 0 (0-30) 0 (0) 
Wait and get over 
naturally 
31.6 
51.7 
11.9 
3.1 
1.8 
Waiting 
Preference 
(n=98) 
50.6 (16.8) 
70.4 
73.5 
23.5 
3.0 
30.6 
10.2 
33.7 
25.5 
12.2 
1.96 (0.9) 
1 (0-14) 
65.3 
31.0 
42.9 
26.2 
1 (0-6) 
0 (0-1) 
0 (0-3) 
0 (0) 
0 (0) 
Total 
(n=573) 
46.1 (15.9) 
79.1 
83.8 
13.3 
3.0 
31.9 
7.9 
48.0 
12.2 
32.5 
2.09 (0.8) 
1 (0-14) 
55.0 
33.7 
33.0 
33.3 
1 (0-30) 
0(0-12) 
0 (0-15) 
0 (0-20) 
0 (0-30) 
* P < 0.05; P-values determined by oneway ANOVA or Kruskai-Wallis test for continuous variables; Pearson's chi-square 
for categorical variables. 
** P < 0.0001; P-values determined by oneway ANOVA or Kruskai-Wallis test for continuous variables; Pearson's chi-
square for categorical variables. 
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Table 3. Mean (SD) SCL-20 Scores by Preference Group* 
Group Baseline 1 month 3 months 6 months 9 months 
Strong antidepressant 1.86 (0.76) 1.19 (0.71) 0.96 (0.67) 0.78 (0.66) 0.75 (0.63) 
reference 
Mild antidepressant 1.68 (0.66) 1.09 (0.62) 0.95 (0.68) 0.92 (0.66) 0.82 (0.64) 
preference 
Counseling preference 1.52 (0.74) 0.96 (0.62) 0.81 (0.56) 0.85 (0.66) 0.79 (0.71) 
Waiting preference 1.43 (0.82) 0.92 (0.62) 0.82 (0.71) 0.73 (0.60) 0.68 (0.60) 
P-value** 0.0001 0.0079 0.2056 0.0947 0.4596 
"SCL-20 indicates the Symptoms Checklist 20; lower scores indicate fewer depressive symptoms. 
"" Determined using oneway ANOVA. 
Figure 2. Mean SCL-20 Scores by Preference Group 
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Table 4. Mean (SD) MCS-12 Scores by Preference Group* 
Group 
Strong antidepressant 
preference 
Mild antidepressant 
reference 
Baseline 
28.3 (10.6) 
32.4 (1 0.5) 
1 month 3 months 
41.0 (11.1) 45.4 (11.0) 
42.9 (10.1) 45.9 (1 0.8) 
6 months 9 months 
48.5 (9.5) 49.6 (9.7) 
46.3 (10.3) 47.7 (9.7) 
Counseling preference 36.2 (12.4) 47.2 (9.8) 49.4 (10.1) 48.2 (10.9) 50.7 (9.9) 
Waiting preference 36.7 (13.0) 46.3 (10.7) 48.5 (11.3) 48.5 (10.9) 49.3 (10.9) 
P-value** < 0.0001 0.0001 0.0340 0.1479 0.1272 
* MCS~12 indicates the Medical Outcomes Survey 12-ltem Short-Form Health Survey Mental Component Summary; 
higher scores indicate better functional status. 
** Determined using oneway ANOVA. 
Figure 3. Mean MCS-12 Scores by Preference Group 
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Table 5. Mean (SD) Change in SCL-20 Scores From Baseline by Preference Group* 
Variable 
Strong antidepressant 
preference 
Mild antidepressant 
preference 
1 month 
-0.65 (0.6) 
-0.59 (0.6) 
3 months 
·0.89 (0.8) 
-0.72 (0.7) 
6 months 9 months 
·1.09 (0.8) -1.10 (0.8) 
-0.75 (0.7) -0.87 (0.7) 
Counseling preference -0.60 (0.7) -0.72 (0.6) -0.61 (0.7) -0.73 (0.8) 
Waiting preference -0.48 (0.7) -0.62 (0.8) -0.72 (0.7) -0.75 (0.8) 
* SCL-20 indicates the Symptoms Checklist 20; lower scores indicate fewer depressive symptoms. 
Figure 4. Mean Change in SCL-20 Scores from Baseline by Preference Group 
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Table 6. Mean (SO) Change in MCS-12 Scores From Baseline by Preference Group* 
Variable 
Strong antidepressant 
preference 
Mild antidepressant 
preference 
1 month 
12.4 (10.4) 
10.6 (9.5) 
3 months 
16.9 (12.1) 
13.4 (12.2) 
6 months 9 months 
20.3 (13.2) 21.1 (13.5) 
13.5 (11.4) 15.3 (11.4) 
Counselingpreference 11.7(11.0) 13.2(11.1) 10.9(11.8) 14.2(12.6) 
Waiting preference 10.2 (1 0.9) 12.5 (13.4) 11.9 (13.5) 11.9 (13.5) 
* MCS-12 indicates the Medical Outcomes Survey i2-ltem Short-Form Health Survey Mental Component Summary; 
higher scores indicate better functional status. 
Figure 5. Mean Change in MCS-12 Scores from Baseline by Preference Group 
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Figure 6 Predicted Mean SCL-20 Scores Based on Linear Mixed-Effects Model* 
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* SCL-20 indicates the Symptoms Checklist 20; lower scores indicate fewer depressive symptoms. 
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Figure 7 Predicted Mean MCS-12 Scores Based on Linear Mixed-Effects Model* 
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* MCS~12 indicates the Medical Outcomes Survey 12-ltem Short-Form Health Swvey Mental Component Summary; 
higher scores indicate better functional status. 
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